Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 19, Citi analyst Yigal Nochomovitz maintained a Buy rating on Olema Pharmaceuticals Inc. (NASDAQ:OLMA) and set a price target of $60. Meanwhile, on February 11, Stifel initiated coverage of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) with a Buy rating and $48 price target, saying that it conservatively modeled peak sales estimates ...

Core Viewpoint - Olema Pharmaceuticals (NASDAQ:OLMA) is identified as a promising investment opportunity with significant upside potential, particularly in the biotechnology sector focused on women's cancers [1][2]. Group 1: Company Overview - Olema Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing therapies for women's cancers, specifically targeting ER+/HER2- breast cancer [3]. - The company's lead program, Palazestrant (OP-1250), is currently in Phase 3 clinical trials aimed at treating metastatic breast cancer [3]. Group 2: Market Potential - The peak sales for Palazestrant are projected to reach $3.1 billion by 2035, indicating substantial future revenue potential [2]. - The global market opportunity for endocrine therapy in ER+HER2 is estimated to exceed $20 billion, suggesting ample space for multiple major players in the market [2]. Group 3: Analyst Ratings - Laura Prendergast from Stifel Nicolaus initiated coverage of Olema Pharmaceuticals with a Buy rating and a price target of $48, indicating over 102% upside potential for investors [1]. - Michael Yee from UBS also assigned a Buy rating with the same price target of $48, citing a more favorable outlook for the biotech segment following a challenging period [2].

Core Thesis - Edwards Lifesciences Corporation is experiencing a bullish sentiment driven by substantial institutional order flow and a strategic "Risk Reversal" trade, indicating confidence in a significant fundamental breakout in Q1 2026 [1][2]. Institutional Order Flow - The company has seen a notable institutional order flow, highlighted by a "Risk Reversal" trade involving the purchase of 2,600 March 20, 2026, $92.50 calls while selling 2,600 $82.50 puts, creating a near-zero-cost upside position [2][3]. Options Strategy - This options strategy takes advantage of the volatility skew, where downside puts are overpriced compared to upside calls, allowing the institutional trader to finance the call purchase by selling expensive puts [3]. Price Support - The $82.50 strike price serves as a calculated floor, positioned just below the 200-day moving average of $83.56, indicating confidence that institutional support will mitigate any near-term downside [3]. Upcoming Catalysts - The timing of the March expiration coincides with key events: the J.P. Morgan Healthcare Conference in January 2026, Q4 earnings and 2026 guidance in early February, and expected FDA approval of the SAPIEN M3 Transcatheter Mitral Valve Replacement system in Q1 2026 [4]. Market Opportunity - Regulatory approval of the SAPIEN M3 system could unlock a multibillion-dollar market opportunity, significantly enhancing the value of the $92.50 calls [5]. Growth Metrics - Edwards' Transcatheter Mitral and Tricuspid Therapies unit is experiencing robust growth at 57% year-over-year, supported by ongoing institutional accumulation and a $500 million accelerated share repurchase program [5]. Investment Outlook - The institutional positioning presents an asymmetric opportunity with high probability downside protection and substantial upside potential, suggesting a target price of $100 in Q1 2026 while defending the $82 level [6].

Core Viewpoint - Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is identified as a promising small-cap stock with significant growth potential, particularly due to its drug Palazestrant, which targets ER+/HER2- breast cancer [1][2]. Group 1: Analyst Ratings and Price Targets - Sam Slutsky from LifeSci Capital has reiterated a Buy rating on Olema Pharmaceuticals and raised the price target from $39 to $45 [1]. - Kelsey Goodwin from Piper Sandler also maintained a Buy rating with a price target of $40 [1]. Group 2: Drug Development and Market Potential - The bullish rating from Piper Sandler is primarily based on the capabilities of Palazestrant, which is expected to be a best-in-class treatment for ER+/HER2- breast cancer due to its complete ER antagonism and degradation ability [2]. - Olema Pharmaceuticals is planning multiple phase 3 trials for Palazestrant in 2026, which could further enhance the stock's value [3]. - The company anticipates launching Palazestrant by next year, indicating a strong focus on developing treatments for breast cancer and other serious diseases [3].

Group 1 - U.S. stock futures are lower, with Dow futures down approximately 100 points [1] - Glaukos Corp reported preliminary FY25 sales of $507 million, leading to a 12.1% drop in shares to $96.97 in pre-market trading [1] Group 2 - Briacell Therapeutics Corp experienced a significant decline of 53.1% to $5.12 after announcing a $30 million public offering [2] - Trip.com Group Ltd shares fell 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [2] - Pearson PLC shares decreased by 7.2% to $13.36 following a trading update for 2025 [2] - Olema Pharmaceuticals Inc shares declined 5.5% to $26.37 after a previous drop of 3% [2] - Fresenius Medical Care AG shares fell 4.8% to $21.79 [2] - Ambitions Enterprise Management Co LLC shares dropped 4.3% to $11.81 after a significant increase of 134% the previous day [2] - NovaBay Pharmaceuticals Inc shares decreased by 3.8% to $12.55 following a 3% drop on Tuesday [2] - SmartRent Inc shares fell 2.3% to $1.74 in pre-market trading [2]

Company Overview - Olema Pharmaceuticals is a biotechnology company focused on therapies for women's cancers, particularly breast cancer, with a strategy centered on advancing its proprietary drug candidate, OP-1250, through clinical development to meet significant unmet medical needs [1] Stock Performance and Transactions - The weighted average sale price of Olema Pharmaceuticals' stock was approximately $29.73 per share, which is 7.5% higher than the market close of $27.93 on December 19, reflecting a one-year total return of 326.50% as of the transaction date [2] - Ian T. Clark, a board member, executed a disposition of 264,800 shares through an option exercise and immediate sale, resulting in a complete exit from direct equity holdings, with 100% of his pre-trade shares disposed of [4][5] - The transaction was driven by option-related mechanics rather than a long-held equity sale, indicating a strategic move to capitalize on the stock's significant appreciation [3][8] Financial Performance - Olema's research and development spending increased to $40.0 million in Q3, reflecting the expansion of Phase 3 programs, while the net loss widened to $42.2 million from $34.6 million a year earlier, consistent with increased clinical activity [7] - The company ended the quarter with $329 million in cash, cash equivalents, and marketable securities, providing a financial runway into 2028 as it advances multiple late-stage trials [7] - A significant equity raise of $218.5 million was completed in late November, strengthening the company's balance sheet [7] Market Sentiment - Sentiment for Olema Pharmaceuticals has shifted rapidly, with most of the stock's explosive growth occurring since late November, driven by analyst upgrades and positive clinical updates for palazestrant [6]

Core Insights - The ALPS Medical Breakthroughs ETF (SBIO) has surged 10.51% in November, nearing its 52-week high of $51.87, driven by positive clinical trial data and increased merger activity in small- and mid-cap biotech companies [1][2] Performance and Inflows - SBIO outperformed the Nasdaq Biotechnology Index, which gained 8.5% in November, as investors shifted focus to smaller companies with drugs in late-stage development [2] - The ETF attracted $19.54 million in net inflows over the past month, bringing total assets to $116.8 million [2] Investment Strategy - SBIO targets biotech companies with at least one drug in Phase II or III clinical trials, focusing on firms with near-term catalysts while avoiding early-stage companies [3] - The fund benefits from improved financing conditions due to Federal Reserve rate cuts, which support long-duration growth stories like drug pipelines [6] Notable Performers - Terns Pharmaceuticals, Inc. (TERN) saw a 240.3% increase after positive Phase I data for its chronic myeloid leukemia candidate [4] - Olema Pharmaceuticals, Inc. (OLMA) gained 215.7% following Roche's successful Phase III results for its oral breast cancer treatment, prompting a reassessment of Olema's late-stage drug opportunities [5] Market Trends - Biopharma mergers and acquisitions in 2025 have already exceeded last year's totals, as large pharmaceutical companies seek to replenish pipelines ahead of a wave of patent expirations [8] - SBIO has achieved a return of approximately 71.8% over the past six months, outperforming the S&P Biotechnology Select Industry Index by over 16 percentage points and the S&P 500 Index by more than 55 percentage points [7]

Group 1 - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 100 points on Monday [1] - Kyverna Therapeutics Inc shares surged 31% to $11.49 following the announcement of topline data from the KYSA-8 Phase 2 trial [2][3] - The KYSA-8 trial involved mivocabtagene autoleucel (miv-cel), a CAR T-cell therapy targeting stiff person syndrome [1] Group 2 - Other notable stock gains included Beneficient, which increased by 29.3% to $6.21, and Immunome Inc, which rose 25.5% to $24.56 after positive results from its Phase 3 trial [3] - Falcon's Beyond Global Inc gained 14% to $12.83, while XBP Global Holdings Inc surged 11.5% to $6.39 [3] - Almonty Industries Inc announced a voluntary withdrawal of its base shelf prospectus, leading to a 9.1% increase in its stock price to $7.38 [3]

Core Insights - Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) reached a four-year high, driven by a price target increase from Jefferies [1][2] - The stock price increased by 15.43% to close at $30.68 after hitting an intra-day high of $30.97 [1] - Jefferies raised its price target for Olema from $30 to $43, indicating a 40% upside potential [2] Company Developments - Olema is conducting a clinical trial for its breast cancer therapy, palazestrant [3] - The performance of next-generation oral Selective Estrogen Receptor Degraders (SERDs) is validating the drug class, which is expected to positively impact upcoming first-line treatment trials [3] - The breast cancer treatment market presents an estimated revenue opportunity of $10 billion [3]

Core Insights - U.S. stocks exhibited mixed performance, with the Nasdaq Composite declining by over 100 points on Wednesday [1] - Daktronics, Inc. reported quarterly earnings of 35 cents per share, surpassing the analyst consensus estimate of 27 cents per share, and quarterly sales of $229.253 million, exceeding the consensus estimate of $214.077 million [1] Company Performance - Daktronics shares surged by 15.7% to $20.80 following the positive earnings report [2] - Photronics, Inc. saw its shares increase by 44% to $37.00 after reporting better-than-expected fourth-quarter results and issuing optimistic first-quarter guidance [3] - Nextdoor Holdings, Inc. gained 24.6% to $2.5050 after a positive social media mention regarding its valuation [3] - Braze, Inc. rose by 17.5% to $36.00 after raising its FY2026 adjusted EPS and sales guidance [3] - Dave & Buster's Entertainment, Inc. jumped 14% to $20.50 following its third-quarter results [3] - SuperX AI Technology Limited's shares increased by 13.8% to $19.63 [3] - GE Vernova Inc. rose by 11.8% to $699.59 after raising its FY28 outlook and dividend, along with expanding its buyback authorization [3] - DBV Technologies S.A. gained 11.2% to $19.09 [3] - Warby Parker Inc. rose by 11% to $25.77 [3] - Dyne Therapeutics, Inc. increased by 10.5% to $20.38 after announcing a $350 million public offering [3] - ABIVAX Société Anonyme rose by 8.6% to $133.24 [3] - Olema Pharmaceuticals, Inc. gained 8.1% to $28.67 [3] - The Middleby Corporation rose by 6.3% to $137.15 after an upgrade from Jefferies [3] - EchoStar Corporation increased by 5.6% to $98.80 following an upgrade from Morgan Stanley [3]